Formulation: A solution in methyl acetate
Formal Name: (Z)-7-((1R,2R,3R)-3-hydroxy-5-oxo-2-((E)-3-oxooct-1-en-1-yl-5,5,6,6,7,7,8,8,8-d9)cyclopentyl)hept-5-enoic acid
Purity: ≥99% deuterated forms (d1-d9)
Formula Markup: C20H21D9O5
Formula Weight: 359,5
Shelf life (days): 730
CAS Number: 2738376-66-2
Notes: 15-keto Prostaglandin E2-d9 (15-keto PGE2-d9) is intended for use as an internal standard for the quantification of 15-keto PGE2 (Item No. 14720) by GC- or LC-MS. 15-keto PGE2 is a metabolite of PGE2 (Item No. 14010) formed by 15-hydroxy prostaglandin dehydrogenase (15-PGDH).{2777} Unlike PGE2, 15-keto PGE2 does not bind effectively to the PGE2 receptors EP2 and EP4 expressed in CHO cells (Kis = 2.6 and 15 µM, respectively) or induce adenylate cyclase activity in the same cells (EC50s = 1.8 and >33 µM, respectively). However, it does bind to EP2 and EP4 in HEK cells expressing these receptors (IC50s = 0.117 and 2.82 µM, respectively), as well as induces cAMP formation (EC50s = 0.137 and 0.426 µM, respectively) and the transcriptional activity of β-catenin/TCF in the same cells.{57866} 15-keto PGE2 inhibits CD3-CD28-MHC-I-induced proliferation of isolated human CD4+ T cells in a concentration-dependent manner.{57867} It also reduces mortality in a mouse model of LPS-induced sepsis when administered at a dose of 15 mg/kg.{57868} a Kd = 1 nM for PGE2).{2777}